Following MAH pilot, WuXi STA to support Antengene oncology research

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/Jirsk)
(Image: Getty/Jirsk)

Related tags: Oncology, marketing authorization, Marketing, Packaging, API

STA Pharmaceutical has entered an agreement with China-based Antengene to provide R&D for its oncology pipeline using its ‘end-to-end’ CMC platform.

The agreement between the Chinese contract development and manufacturing organization (CDMO) STA Pharmaceutical, a WuXi AppTec company, and Antengene, follows China’s 2016 Marketing Authorization Holder (MAH)​ pilot program.

The MAH program​ allows drug license holders to use a third party manufacturer instead of building GMP manufacturing capabilities in-house, as was previously required.

Jinling Chen, VP of pharmaceutical development services at STA Pharmaceutical, a WuXi AppTec company, told us the company was the first CDMO to support a drug launch through the MAH program. 

As an integrated CDMO, Chen explained that having both its drug substance and drug product research and development (R&D) services in the same facility enables “frictionless”​ communication as the molecule moves down the pipeline.

“Making the drug substance and drug product in one company in close proximity, working together with a shared quality program saves critical time in the race to reach patients,” ​said Chen.

"Having the supply chain within one company, with each group is geographic proximity, saves time in shipping, release testing, and method transfers," ​she added.

Related news

Show more

Related products

show more

Import Risks & Clinical Supply Depots

Import Risks & Clinical Supply Depots

Catalent Pharma Solutions | 07-Nov-2018 | Case Study

A sponsor running a clinical trial in Israel arranged to ship their clinical trial product from Europe to a depot in Israel. With the protocol based in...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Discover Fermion’s new API unit 4 in Hanko

Discover Fermion’s new API unit 4 in Hanko

Recorded the 04-Sep-2018 | Webinar

Join this webinar to learn more about Fermion’s new manufacturing unit 4 at the Hanko site. This webinar will provide virtual tour to our new state of...

Related suppliers

Follow us

Featured Events

View more


View more